Company intelligence / Profile preview

EndoRel Biosciences

Portland, Oregon, United Statesendorelbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EndoRel Biosciences is an early-stage biotechnology company developing a proprietary peptide-based platform to enhance the cytosolic delivery of RNA therapeutics and antibody-drug conjugates. The company’s initial focus is on integrating its endosomal release peptides with ADCs for improved intracellular targeting. No clinical results have been reported as of June 2025.

Therapeutic areas: Other
Modalities: Peptide-based delivery technologyRNA therapeuticsAntibody-drug conjugates (ADCs)Therapeutic antibodies/antibody fragments
Industry: Biotech

Partnerships

Collaborators and customers in the field of drug efficacy and safety improvement through better intracellular delivery; specific partners not named

Beyond the preview

Go deeper on EndoRel Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoRel Biosciences.

Explore the full profile